TLR9 and neoplasm: The combination therapy of TLR3 agonist with a TLR9 agonist (CpG: 5’-cytosine-phosphate-guanine-3’) along with adoptive T cell transfer (ACT) has shown promise in increasing the abundance of various immune cell types, including B cells with CD4+ and CD8+ T cells, macrophages, neutrophils, and NK cells in tumor-draining lymph nodes (107).